

Ref: 27/SE/LC/2024-25

Date: 28/06/2024

To,
Head,
Listing Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers Dalal
Street,
Mumbai - 400 001.

Head, Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1. G Block,
Bandra -Kurla Complex, Bandra (East),
Mumbai- 400051

Scrip Code: 544122

Scrip Symbol: ENTERO

Dear Sir/Madam,

Subject: Outcome of Board Meeting

Reference: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. ("LODR")

With reference to the captioned subject matter, we would like to inform that the Board of Directors of Entero Healthcare Solutions Limited ("**Company**") has approved, inter-alia, to execute the definitive agreements to acquire 100% paid-up equity share capital of Devi Pharma Wellness Private Limited ("**DPWPL**") at their meeting held today i.e. June 28, 2024.

The details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July, 2023 are as under:

Sr. No.	Particulars	Details
a	Name of the target entity, details in brief such as size, turnover etc.	<p>Devi Pharma Wellness Private Limited, a company incorporated in Thiruvananthapuram, Kerala, India, bearing CIN U46497KL2024PTC088322 ("DPWPL").</p> <p>DPWPL is engaged in the business of wholesale distribution of pharmaceuticals and other allied products.</p> <p>Paid-up equity share capital of DPWPL is INR. 1,00,000/- (Indian Rupees One Lakhs Only).</p>

Sr. No.	Particulars	Details
		The turnover of DPWPL is NIL as DPWPL was incorporated as on June 25, 2024.
b.	whether the acquisition would fall within related party transaction(s) and whether the promoter/promoter group/group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm s length"	No, the acquisition shall not fall within related party transaction and promoter/promoter group/group companies does not have any interest in the DPWPL.
c.	industry to which the entity being acquired belongs	DPWPL operates in same line of business activity i.e. business of distribution of pharmaceuticals, surgical and other healthcare and allied products.
d.	objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	The business of DPWPL is in line of the business of the Company i.e. wholesale distribution of pharmaceutical and other allied products and the acquisition of DPWPL by the Company shall enable the Company to expand its business in the State of Kerala and thereby enabling the Company to generate additional business and revenue on consolidated basis.
e.	brief details of any governmental or regulatory approvals required for the acquisition;	Not applicable.
f.	indicative time period for completion of the acquisition;	The acquisition shall be completed by August 15, 2024.

Sr. No.	Particulars	Details
G.	consideration whether cash consideration or share swap or any other form and details of the same	The acquisition of DPWPL will be through cash consideration.
h.	cost of acquisition and/ or the price at which the shares are acquired;	<p>10,000 equity shares of DPWPL will be acquired at INR 10 (Indian Rupees Ten only) per equity share at total amount of Rs. 100,000/- (Indian Rupees One Lakh only).</p> <p><i>Note: DPWPL is considering acquisition of business undertakings of M/s. Devi Pharma, having Mr. K.S. Balagopal, Mrs. Manjula Balagopal and Mr. Muralikrishna B as partners in the Partnership firm, as a going concern on a slump sale basis, which is in the business of wholesale distribution of pharmaceutical products, surgical and other healthcare and allied products.</i></p> <p><i>The slump sale amount payable shall be discharged by DPWPL. Details of revenue pertaining to M/s. Devi Pharma, for last three years, has been summarized in Annexure I.</i></p>
i	percentage of shareholding / control acquired and / or number of shares acquired;	Company is proposed to acquire 10,000 (Ten Thousand) equity shares of face value INR 10/- (Indian Rupees Ten only) each, equivalent to 100% (Hundred percent) of the total issued and paid-up equity share capital of DPWPL.
j	brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other	DPWPL is engaged in the business of wholesale distribution of pharmaceutical and other allied products. DPWPL was incorporated on June 25, 2024 and thus the turnover of DPWPL is NIL. DPWPL conducts its business only in India.

Sr. No.	Particulars	Details
	significant information (in brief);	

The Board Meeting commenced at 6:00 PM (IST) and concluded at 6:45 PM (IST).

This is for your information and records.

Yours Faithfully,
For **Entero Healthcare Solutions Limited**

Jayant Prakash
General Counsel, Company Secretary & Compliance Officer
(Mem: F6742)

Annexure I

DPWPL shall acquire business undertakings of M/s. Devi Pharma. Details of revenue are mentioned below:

Figures in Rs. Mn

Name of the Firm	F.Y - 2023-2024 (Unaudited)	F.Y - 2022-2023 (Audited)	F.Y - 2021-2022 (Audited)
<i>M/s. Devi Pharma</i>	1,492	1,377	1,275
Total	1,492	1,377	1,275